PHOTO FILE: A woman holding a small bottle labeled “COVID-19 vaccine” and a medical syringe in this illustration were taken on April 10, 2020. REUTERS / Dado Ruvic / Illustration
LONDON (Reuters) – The first results from the largest randomized drug trial in the world to treat COVID-19 patients can be available in early July, one of the scientists who led the UK-based study named Recovery said on Tuesday.
The first data from this study, which tested existing drug options, were probably derived from a type of steroid called low-dose Dexamethasone and used to reduce inflammation, said Martin Landray, professor of medicine and epidemiology in the Nuffield Department of Population Health at Oxford University.
The trial so far has registered 11,000 patients ranging in age from one to 109 in 175 hospitals in the UK since it was founded in March, he told reporters at a briefing.
“There can’t be one big win” from the trial, which is why the project is testing some existing drugs to see if they might be used again to help treat COVID-19, he said.
“At present we really don’t have any treatment, so the first results will give us guidance,” he said.
Other drugs being tested are the anti-malaria hydroxychloroquine drug, Lopinavir-Ritonavir, which is used to treat HIV, an antibiotic called Azithromycin and healing plasma, which is collected from people who have recovered from the virus and contain antibodies to fight it.
(This story has been corrected to make it clear in the headlines that the first results, not the trial, are expected in July)
Reporting by Josephine Mason and Kate Kelland; Editing by Gareth Jones
to request modification Contact us at Here or [email protected]